What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the efficacy and safety of allogeneic dual-target CAR T-cell therapy in patients with refractory systemic lupus erythematosus.

December 8, 2025BloodOpen Access

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

View Full Paper

Ask AI

Bookmark

Authors

RGRunxia Gu KLKe Li SWShuning Wei

Discussion

Member takes

Overview

Investigator-initiated trial found CAR T-cell therapy induced complete response in refractory thrombocytopenia, suggesting a novel treatment approach.

Key Points

To evaluate the efficacy and safety of allogeneic dual-target CAR T-cell therapy in patients with refractory systemic lupus erythematosus.
Investigator-initiated trial using QT-019B to eliminate autoantibody-producing cells.
Six patients with refractory SLE-ITP received a single infusion after lymphodepleting conditioning with fludarabine and cyclophosphamide.
Dose escalation approach was implemented (3+3 design) to determine safety and efficacy.
Four patients completed the dose-limiting toxicity observation period; three out of four achieved complete response.
Platelet counts normalized within one month for responding patients, with sustained improvement.
All autoantibodies tested became negative in responders by Day 28, indicating effective treatment.

Cite This Study

Gu et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e566 https://doi.org/10.1182/blood-2025-3031

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

View Full Paper

Ask AI

Bookmark

Authors

RGRunxia Gu KLKe Li SWShuning Wei

Discussion

Member takes

Overview

Investigator-initiated trial found CAR T-cell therapy induced complete response in refractory thrombocytopenia, suggesting a novel treatment approach.

Key Points

To evaluate the efficacy and safety of allogeneic dual-target CAR T-cell therapy in patients with refractory systemic lupus erythematosus.
Investigator-initiated trial using QT-019B to eliminate autoantibody-producing cells.
Six patients with refractory SLE-ITP received a single infusion after lymphodepleting conditioning with fludarabine and cyclophosphamide.
Dose escalation approach was implemented (3+3 design) to determine safety and efficacy.
Four patients completed the dose-limiting toxicity observation period; three out of four achieved complete response.
Platelet counts normalized within one month for responding patients, with sustained improvement.
All autoantibodies tested became negative in responders by Day 28, indicating effective treatment.

Cite This Study

Gu et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e566 https://doi.org/10.1182/blood-2025-3031

View Full Paper

Ask AI

Bookmark